TY - JOUR T1 - Highlights from this issue JF - Thorax JO - Thorax SP - 1 LP - 1 DO - 10.1136/thoraxjnl-2019-214381 VL - 75 IS - 1 AU - The Triumvirate Y1 - 2020/01/01 UR - http://thorax.bmj.com/content/75/1/1.abstract N2 - “I’ve got 20:20 vision and that’s all I need: enough to keep my baby for company.”The words of blues legend Rory Gallagher: “Ireland’s Jimi Hendrix”. At Thorax, we would like to keep you, our readership, for company in 2020. To do so, we bring you our new impact factor of 10.307 and a clutch of original and impactful manuscripts in this month’s issue!Global deaths from TB were estimated to be 1.3 million in 2016. Annually, 700 000 people receive treatment for recurrent TB and 480 000 for multidrug-resistant TB. Both involve administering injectable drugs for at least 60 days. The problem persists into the third decade of the 21st century. In this month’s journal, Cohen and colleagues (see page 64) describe a randomised controlled, non-inferiority trial of hospital administration of injectable drugs versus home administration by a lay “guardian”, conducted in Malawi. Recruitment proved difficult. The recruitment target was 268 patients and recruitment was stopped at 204 patients for futility. Non-inferiority could not be demonstrated. However no difference was found, between regimens, in the number of patients alive and on treatment at 60 days. Home treatment was … ER -